TBPH Reports $17.7M YUPELRI Rev, $873M TRELEGY Sales, $395M Cash, $20M Milestone Target, 20% OpExp Cut, All Hatch-Waxman Litigation Resolved
Theravance Biopharma, Inc. · PHARMACEUTICAL PREPARATIONS · Now $15.94
-4.5% in 7d after detection
Post-detection moves
1h
—
1d
-0.1%
3d
-3.2%
7d
-4.5%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS